<DOC>
	<DOCNO>NCT01686152</DOCNO>
	<brief_summary>To determine comparability safety efficacy Imiquimod Cream , 3.75 % Zyclara ( imiquimod ) Cream , 3.75 % ( reference list drug ) subject actinic keratosis ( AK ) face bald scalp . It also determine whether efficacy two active treatment superior Vehicle cream .</brief_summary>
	<brief_title>Study Comparing Imiquimod Cream , 3.75 % Zyclara® ( Imiquimod ) Cream , 3.75 % Treatment Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Willing able provide write informed consent study At least 18 year age . Immunocompetent male nonpregnant nonlactating female . Each female subject childbearing potential ( exclude woman surgically sterilize postmenopausal least 2 year ) , addition negative urine pregnancy test Visit 1/Day 1 , must willing use acceptable form birth control study . For purpose study , follow consider acceptable method birth control : oral contraceptive , contraceptive patch , contraceptive implant , vaginal contraceptive , doublebarrier method ( example , condom spermicide ) , contraceptive injection ( DepoProvera® ) , intrauterine device ( IUD ) , hormonal IUD ( Mirena® ) , abstinence document second acceptable method birth control subject become sexually active . Subjects enter study hormonal contraceptive ( oral contraceptive , patch injection ) must method least 3 month ( 90 day ) prior study continue method duration study . Subjects use hormonal contraception ( oral contraceptive , patch injection ) stop must stop less 3 month ( 90 day ) prior baseline . Subjects enter study use contraceptive implant intrauterine contraceptive must method least 6 month ( 180 day ) continue duration study stop must stop less 6 month ( 180 day ) prior baseline . Clinical diagnosis AK , define ≥ 5 ≤ 20 clinically typical , visible palpable AK lesion , least 4 mm diameter , area exceeds 25 cm2 either face ( exclude ear ) bald scalp , face scalp . In general good health free clinically significant disease , AK , might interfere study evaluation . Willing able understand comply requirement study , apply IP instruct , attend require visit , comply therapy prohibition , able complete study . Presence atopic dermatitis , basal cell carcinoma , eczema , psoriasis , rosacea , squamous cell carcinoma , possible confound skin condition treatment area either face bald scalp . Clinically significant systemic disease ( immunological deficiency ) , unstable medical disorder , lifethreatening disease , current malignancy . Use face bald scalp chemical peel , dermabrasion , laser abrasion , psoralen plus ultraviolet A ( PUVA ) therapy , and/or ultraviolet B ( UVB ) therapy last 6 month ( 180 day ) Use systemic cancer chemotherapy medication last 6 month ( 180 day ) Use face bald scalp cryodestruction chemodestruction , curettage , photodynamic therapy , surgical excision , topical 5fluorouracil , topical corticosteroid , topical diclofenac , topical imiquimod , topical retinoids , masoprocol , treatment AK last 1 month ( 30 day ) Immunomodulators immunosuppressive therapy , interferon , oral/systemic corticosteroid , cytotoxic drug last 1 month ( 30 day ) . Intranasal inhale corticosteroid acceptable keep constant throughout study . Need intent continue use treatment list four point current study Known hypersensitivity allergy imiquimod component IP ( dosage form ) . Females pregnant , breastfeeding , intend become pregnant study , agree use acceptable form birth control study . Any clinically significant condition situation condition study , opinion investigator , would interfere study evaluation optimal participation study . Use investigational drug investigational device within 1 month ( 30 day ) prior randomization . Previous participation study . Sunburn designate treatment area treat study entry . Current involvement activity require excessive prolonged sun exposure . Consumption excessive amount alcohol , abuse drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>